This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Orion Corporation Signs License Agreement With Janssen Pharmaceuticals, Inc. For The Development And Commercialization Of Its Novel Treatment For Alzheimer's Disease

ESPOO, Finland, Dec. 19, 2013 (GLOBE NEWSWIRE) -- ORION CORPORATION     STOCK EXCHANGE RELEASE 19 DECEMBER 2013 at 7.45 p.m. EET

Orion Corporation (Nasdaq OMX Helsinki: ORNAV and ORNBV) announced today that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. for the development and commercialization of Orion's novel, investigational alpha-2c adrenoceptor antagonists f or the symptoms of Alzheimer's disease, including a clinical phase compound OR M-12741 .

According to the agreement, Orion will receive an upfront payment of USD 31 million and is eligible to receive milestone payments from Janssen upon successful completion of certain development and commercialization events, as well as royalties on future sales . Orion will use the majority of the up-front payment over the next few years against the costs of the additional Phase IIa study sponsored by Orion.

Under the terms of the agreement, Orion will have exclusive commercialization rights in Europe and will grant Janssen a worldwide exclusive license to develop ORM-12741 and other compounds of alpha-2c platform. Janssen will have an exclusive right to commercialize these compounds outside Europe. Orion and Janssen will co-fund the development after an additional Phase IIa study is completed successfully by Orion.

The agreement causes no change on Orion's full-year 2013 outlook.

Dr . Reijo Salonen, Senior Vice President of R&D at Orion commented:

"In our collaboration with Janssen, I believe we will have the best of all worlds," said Dr. Reijo Salonen, SVP R&D and Chief Medical Officer for Orion. "At Janssen, there is a track record of success and commitment of developing therapies in Neurosciences; at Orion, we have a track record of inventing innovative molecules; and for Alzheimer patients, we hope that this partnership will bring them a novel medicine that will make an important difference to their lives."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,063.99 -168.03 -0.92%
S&P 500 2,108.24 -17.82 -0.84%
NASDAQ 5,036.0930 -53.2690 -1.05%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs